(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Anticuerpos monoclonales > DA - CIMA - Terapia génica y Hepatología - Anticuerpos monoclonales - Artículos de Revista >

Production of recombinant woodchuck IFNalpha and development of monoclonal antibodies
Autor(es) : Berraondo, P. (Pedro)
Crettaz, J. (Julien)
Ochoa, L. (Laura)
Vales, A. (África)
Ruiz, J. (Juan)
Prieto, J. (Jesús)
Martinez-Anso, E. (Eduardo)
Gonzalez-Aseguinolaza, G. (Gloria)
Palabras clave : 2',5'-Oligoadenylate Synthetase/drug effects
Antibodies, Monoclonal/biosynthesis
Hepatitis B/immunology
Hepatitis B Antibodies/biosynthesis
Interferon-alpha/immunology
Fecha incorporación: 2009
Editorial : Mary Ann Liebert
Versión del editor: http://dx.doi.org/10.1089/jir.2008.0012
ISSN: 1079-9907
Cita: Berraondo P, Crettaz J, Ochoa L, Vales A, Ruiz J, Prieto J, et al. Production of recombinant woodchuck IFNalpha and development of monoclonal antibodies. J Interferon Cytokine Res 2009 Feb;29(2):75-82.
Resumen
Interferon alpha (IFNalpha) is the first line treatment for chronic hepatitis B and C. In order to test new IFNalpha delivery systems and investigate the function of this cytokine in the woodchuck model, the best animal model of chronic hepatitis B, we produced and purified recombinant woodchuck IFNalpha and used it to produce monoclonal antibodies. wIFNalpha5 was cloned in a prokaryotic expression system, expressed as His-tagged protein and then purified. The rwIFNalpha5 protein was found to induce STAT-3 phosphorylation, to enhance 2',5'-oligoadenylate synthetase mRNA levels and to possess a potent antiviral activity. Two monoclonal antibodies were obtained through immunization of rats with rwIFNalpha5. Both recognized rwIFNalpha5 in western blot analysis and one was able to neutralize the antiviral activity of the rwIFNalpha5 and lymphoblastoid IFNalpha preparations. Finally, a capture rwIFNalpha5 ELISA was developed using both antibodies. In summary, the tools generated in this study will allow different forms of IFNalpha delivery as well as different combination therapies in woodchuck hepatitis virus infection to be tested, thus providing useful information for the design of new strategies to treat chronic hepatitis B in humans.
Enlace permanente: http://hdl.handle.net/10171/20304
Aparece en las colecciones: DA - CIMA - Terapia génica y Hepatología - Terapia génica hepatitis virales - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Terapia génica del cáncer - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Anticuerpos monoclonales - Artículos de Revista

Ficheros en este registro:
Fichero:  jir.2008.0012.pdf
Descripción: 
Tamaño:  284,52 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.